Passive immunisation involves administering pre-formed antibody as human immune globulin to a recipient who is thought to have either no natural immunity to one or more infections, or who has impaired antibody production. CSL Behring Australia is the primary manufacturer of the immune globulins (immunoglobulins) for the New Zealand Blood Service (NZBS). Their sterile solutions of immunoglobulin are prepared by fractionating large pools of plasma collected from blood donors to the NZBS.
In New Zealand, blood donations are only collected from voluntary, unpaid donors who are in good health and who do not have any conditions identiﬁable either by the standard questionnaire that all blood donors complete or by the mandatory testing for HIV/AIDS, hepatitis B, hepatitis C and syphilis on each donation. Blood donations are only used if the tests show no evidence that these infections are present.
Immunoglobulin products available in New Zealand include: human normal immunoglobulin for intramuscular (IM) use, specific immunoglobulin for intramuscular use, human normal immunoglobulin for intravenous use (IVIG) and human normal immunoglobulin for subcutaneous use. All of these products have an excellent safety record in both Australia and New Zealand.
Normal Immunoglobulin-VF is a sterile, preservative-free, pasteurised solution containing 160 mg/mL human plasma proteins and 22.5 mg/mL glycine. The solution has a pH of 6.6. At least 98 percent of the protein comprises immunoglobulins, mainly immunoglobulin G (IgG). Normal Immunoglobulin-VF is intended for IM injection and is available in 2 mL and 5 mL vials. It is prepared by Cohn cold ethanol fractionation of human plasma. The manufacturing process involves speciﬁc viral removal steps to reduce the possibility of virus transmission, and includes pasteurisation for viral inactivation and nanofiltration for virus removal.
There are a number of speciﬁc human immunoglobulin preparations for IM use available, including those for tetanus, hepatitis B, varicella zoster and anti-D. These are manufactured from plasma pools containing donations from individuals known to have high levels of the appropriate antibody. These preparations are available in single vials containing the specific antibody. The volume of the product will be determined by the potency for the appropriate antibody. In unusual circumstances, when supplies of speciﬁc immunoglobulin products manufactured from New Zealand plasma are not available from the NZBS, commercial products from alternative donor sources may be supplied.
Other products are held in a limited number of centres for national use. For example, rabies immunoglobulin (RIG) is held at NZBS sites in Auckland, Christchurch and Wellington. These products can be accessed following discussion with an NZBS medical officer.
The current human normal immunoglobulin for intravenous use in New Zealand is Intragam P, produced by CSL Behring Australia. Intragam P is a sterile, preservative-free solution containing 6 g of human protein and 10 g of maltose in each 100 mL. The solution has a pH of 4.25. Isotonicity is achieved by the addition of maltose. At least 98 percent of the protein has the electrophoretic mobility of IgG. At least 90 percent of the protein is IgG monomer and dimer. Intragam P contains only trace amounts of immunoglobulin A (IgA) (nominally <0.025 mg/mL).
It is produced by chromatographic fractionation of large pools of human plasma obtained from voluntary blood donors. The protein has not been chemically or enzymatically modiﬁed. The manufacturing process contains special steps to reduce the possibility of virus transmission, including pasteurisation (heating at 60oC for 10 hours) and incubation at low pH.
Note: in New Zealand, Intragam P is used to provide intravenous tetanus immunoglobulin. Because the level of immunoglobulin in each batch varies, consultation with a medical officer at the NZBS is recommended prior to issuing a prescription.3
Human normal immunoglobulin for subcutaneous use (Evogam) is produced by CSL Behring Australia. It is a sterile solution containing 16 g per 100 mL of total human plasma immunoglobulin with a purity of at least 98 percent immunoglobulin G (IgG). At least 85 percent consists of monomers and dimers (typically >90 percent), and less than 10 percent of the IgG are aggregates. The distribution of the IgG subclasses closely resembles that found in normal human plasma.
The pH value of the ready-to-use solution is 6.6. It contains 2.25 g of glycine in each 100 mL as a stabiliser. It does not contain a carbohydrate stabiliser (eg, sucrose, maltose) and contains no preservative. Evogam contains only trace amounts of IgA, typically <0.025 mg/mL.
It is produced by chromatographic fractionation of large pools of human plasma obtained from New Zealand’s voluntary blood donors. The manufacturing process involves special steps to reduce the possibility of virus transmission, including pasteurisation (heating at 60oC for 10 hours) and nanofiltration.
The NZBS operates a 24-hour on-call service for medical advice and access to these products. Details of the medical officer on call can be obtained from any DHB hospital blood bank in New Zealand. Product can be requested using the NZBS request form. This can be accessed online (www.nzblood.co.nz/Clinical-information/Transfusion-medicine/Information-for-Health-Professionals/Request-forms), or by writing to:
New Zealand Blood Service
Private Bag 92071
Victoria Street West
or (during normal office hours) by:
telephone: (09) 523 2867
fax: (09) 523 5754.
For advice on the use of immunoglobulin products and speciﬁc dosages of these products, please contact a medical officer at the NZBS. Copies of the product data sheet are available on the NZBS website (www.nzblood.co.nz/Clinical-information/Transfusion-medicine/ Health-professionals-medicine-datasheets/Immunoglobulins).
Normal Immunoglobulin-VF is available for passive immunisation (pre- or post-exposure prophylaxis) against measles (see section 11.8.2) and hepatitis A (see section 7.8). It is not recommended for the prevention of rubella or mumps. Guidance on the use of speciﬁc preparations is provided in other sections of this Handbook: for pre- or post-exposure prophylaxis against hepatitis B (sections 8.5.3 and 8.8.1), tetanus (section 19.5.3) and varicella zoster (section 21.8.2).
Recurrent infections can occur in individuals who have low or absent levels of circulating immunoglobulins – so-called humoral immune deﬁciency. This can arise as a congenital disorder, or it can be acquired as a consequence of a number of diseases. Humoral immune deﬁciency can exist alone or as part of a wider immune deﬁciency syndrome. Immunoglobulin products can be used to prevent recurrent infections in these patients.
Until recently, IVIG was the product of choice for managing these patients. A subcutaneous IgG product (Evogam) is also now available, which can be used by patients at home. This avoids the need for day-case admission for infusion of IVIG and is preferred by some patients. The subcutaneous preparation is not suitable for use in prophylaxis against hepatitis A or measles infection.
For replacement therapy in antibody deﬁciency disorders, monthly administration of IVIG is given, usually at a dosage of 0.2 to 0.6 g/kg of body weight.4 Subcutaneous product is administered one to two times per week, with the overall monthly dosage similar to that of IVIG. For both types of product, the dosage and frequency of infusion should be based on the effectiveness in the individual patient. In general, however, the aim of treatment should be to maintain the serum IgG at or above a level of 5 g/L.
Immunoglobulin products must be stored at +2oC to +8oC and must not be frozen. They should also be protected from the light. If the product appears turbid or to contain sediment, it must not be used. Always check and observe the manufacturer’s expiry date before injecting the product. The product does not contain an antimicrobial preservative and must be used immediately after opening the vial, and any unused portions should be discarded. Information on the batch number and dose injected must be kept in the recipient’s records.
The intramuscular and subcutaneous forms of normal immunoglobulin should be brought to room temperature before use. They must not be given intravenously because of the possible reactions discussed in section 22.214.171.124
The intramuscular product, Normal Immunoglobulin-VF, should be given slowly by deep IM injection, using a needle of appropriate gauge and length. If a large volume (more than 5 mL) is required, it is advisable to administer it in divided doses at different sites.
The subcutaneous product, Evogam, is normally given using an infusion pump. Information on infusion rates is provided in the medicine’s data sheet.
Immunoglobulin should not be mixed with other pharmaceutical products, except as indicated by the manufacturer.
Passively acquired antibody can interfere with the response to live attenuated virus vaccines. (Refer to Table 1.3, in section 1.4.2, for the suggested intervals between immunoglobulin product administration or blood transfusion and MMR or varicella live virus vaccines.) If possible, immunoglobulins or other blood products should be deferred for at least three weeks after the administration of a live vaccine.
Note: the above does not apply to rotavirus vaccines.
Inactivated vaccines may be administered concurrently with passive antibody (although in separate syringes) to induce active immunity, as is done for some tetanus-prone wounds and for babies born to hepatitis B surface antigen (HBsAg) positive mothers.
Serological testing after the administration of immunoglobulin may detect the transfused antibodies for several months after administration. Serological testing after immunoglobulin should therefore be discussed with an expert.
The estimated half-life of intramuscular human normal immunoglobulin is 27 ± 7 days (mean ± standard deviation [sd]).4 The duration of effect is linked to the initial dosage.
The estimated half-life of intravenous human normal immunoglobulin is 40 ± 8 days (mean ± sd).4
The estimated half-life of subcutaneous human normal immunoglobulin is 55 days (range 14–165 days).4
Health professionals should check the package insert for the immunoglobulin product to be administered.
Skin tests should not be conducted with immunoglobulin preparations. Intradermal injection of concentrated gammaglobulin may cause a local inﬂammatory reaction, which can be misinterpreted as a positive allergic reaction. Such allergic responses to normal immunoglobulin given in the prescribed IM route are extremely rare, but may occur in those with complete immunoglobulin A (IgA) deﬁciency in whom anti-IgA is present.
Intramuscular injection of immunoglobulin products should be avoided in patients with a low platelet count or with any coagulation disorder that would contraindicate IM injections. In these circumstances, the injection may be given subcutaneously.3
Injections of Normal Immunoglobulin-VF must be IM, and care should be taken to draw back on the plunger of the syringe before injection in order to be certain that the needle is not in a blood vessel (see section 2.3).
As with any injection, there is a risk of anaphylaxis. Adrenaline and other means of treating acute reactions should therefore be immediately available (see section 2.4).
Clinicians in New Zealand are requested to notify all adverse reactions arising from, or in association with, the use of blood products. Reactions to any immunoglobulin product should be reported on a form obtainable from the NZBS or any local DHB hospital blood bank.
Local tenderness, erythema and muscle stiffness occasionally occur at the site of injection and may persist for several hours after intramuscular injection. An occasional recipient may react more strongly, with a low-grade fever. Systemic reactions, including nausea, urticaria and generalised hypersensitivity reactions, may occur.3, 4
Reactions to IVIG tend to be related to the infusion rate and are most likely to occur during the ﬁrst hour of the infusion. However, delayed reactions can occur, and include nausea, vomiting, chest pains, rigors, dizziness or aching legs. Systemic and local reactions are more common in those being treated for hypogammaglobulinaemia than in those with normal gammaglobulin levels who are being treated with immunoglobulin preparations for autoimmune conditions.
There have been occasional reports of renal failure following infusion of IVIG. These largely relate to sucrose-containing products. Intragam P, the product available in New Zealand, does not contain sucrose, but patients should be adequately hydrated prior to its administration. Renal function should be monitored in patients considered to be at increased risk.
Aseptic meningitis has been reported following treatment with IVIG. This may present up to two days following treatment. Anaphylactic reactions, although rare, have been reported following injection of immunoglobulin products, although anaphylaxis is more likely to occur following intravenous infusion.
Immunoglobulin products may interfere with the immune response to live virus vaccines. In general, live vaccines should be given at least 3 weeks before or up to 11 months after the immunoglobulin preparation (see section 1.4.2 and Table 1.3). This does not apply to the yellow fever vaccine, because New Zealand blood donors are very unlikely to have antibodies to this virus. For travellers abroad, the necessary interval may not be possible.